The partnership brings together Salipro’s tech for stabilising drug targets from Boehringer’s drug discovery programmes.

Salipro Biotech has signed a research and license agreement with Boehringer Ingelheim to accelerate the development of ...

The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilise challenging drug targets from Boehringer Ingelheim’s drug discovery programs to enable ...

The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.

Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that the ongoing ion channel research collaboration with Boehringer Ingelheim has been extended with one year. "The p ...

Currently priced at Rs 60 per tablet, Empagliflozin’s generic versions will be available for as low as Rs 9-Rs 14 per tablet, significantly reducing costs for millions of patients, states the report.

Mikael Dolsten, M.D., Ph.D., to its Board of Directors. Dolsten, who served as Pfizer’s chief scientific officer and ...

Dr. Dolsten was most recently CSO of Pfizer and has served in leadership roles at AstraZeneca, Boehringer Ingelheim, Pharmacia, and Wyeth Pharmaceuticals Appointment follows the transition ...

Grünenthal has announced that Professor Dr Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the ...

Tensions escalated further when Mr Kwek Leng Beng sought his son’s removal as group CEO on Feb 8, citing his role in what he called "the latest of a long series of missteps". The board ...